GLSI-100 (GP2 + GM-CSF)
Prevention of recurrence in HLA-A*02+, HER2 3+ breast cancer (adjuvant setting)
Key Facts
About Greenwich LifeSciences
Greenwich LifeSciences is singularly focused on developing GLSI-100, a peptide-based immunotherapy to prevent metastatic recurrence in HER2-positive breast cancer survivors. Its strategy is validated by compelling Phase IIb data showing an 80%+ reduction in recurrence over 5 years and a strong safety profile, which has enabled the launch of a large, global Phase III trial. With a lean operational model, significant insider ownership, and commercial-scale manufacturing already in place, the company is positioned to advance a potential breakthrough in adjuvant cancer care.
View full company profileAbout Greenwich LifeSciences
Greenwich LifeSciences is singularly focused on developing GLSI-100, a peptide-based immunotherapy to prevent metastatic recurrence in HER2-positive breast cancer survivors. Its strategy is validated by compelling Phase IIb data showing an 80%+ reduction in recurrence over 5 years and a strong safety profile, which has enabled the launch of a large, global Phase III trial. With a lean operational model, significant insider ownership, and commercial-scale manufacturing already in place, the company is positioned to advance a potential breakthrough in adjuvant cancer care.
View full company profile